Apomorphine yields positive results from TOLEDO study for Parkinson’s disease

Written by Olivia Stevenson, Future Science Group

Researchers from Britannia Pharmaceuticals Ltd (Reading, UK) have demonstrated that treatment of Parkinson’s disease (PD) patients with apomorphine, known by the tradenames APO-go® and MOVAPO®, can provide relief of persistent motor fluctuations. The improvements in PD symptoms allowed patients to significantly reduce the dose and number of administrations of their other PD medications. Although current medications treat the symptoms of PD, some patients’ symptoms cannot be controlled by oral medication alone. In this study, known as the TOLEDO study and published in Lancet Neurology, researchers gave a subcutaneous infusion of either apomorphine or a placebo over a course of 12...

To view the full article, please register now for access

It's completely free